CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Wu, Y. [1 ,2 ]
Chang, J. [3 ]
Zhang, L. [4 ]
Tu, H. [1 ,2 ]
Wu, L. [5 ]
Feng, J. [6 ]
Lu, S. [7 ]
Zhou, C. [8 ]
Wang, J. [9 ,10 ]
Mok, T. [11 ]
Taylor, F. [12 ]
Mossman, B. [12 ]
Penrod, J. [13 ]
Lawrance, R. [14 ]
Blum, S. [13 ]
Wang, P. F. [13 ]
Cheng, Y. [15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[5] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[6] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[7] Shanghai Jiao Tong Univ Shanghai, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Shanghai Pulm Hosp, Shang, Peoples R China
[9] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
[11] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[12] Adelphi Values, Boston, MA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Adelphi Values, Bollington, England
[15] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 12期
关键词：
Advanced NSCLC; Nivolumab; Docetaxel; Patient-Reported Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10
引用
收藏
页码：S1047 / S1048
页数：2
相关论文
共 50 条
  • [41] Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)
    Fanucchi, M
    Fossella, F
    Fidias, P
    Natale, R
    Belt, R
    Govindan, R
    Raez, L
    Schiller, J
    Kashala, O
    Kelly, K
    LUNG CANCER, 2005, 49 : S30 - S30
  • [42] Long-term patient-reported outcomes after non-small cell lung cancer resection
    Heiden, Brendan T.
    Subramanian, Melanie P.
    Liu, Jingxia
    Keith, Angela
    Engelhardt, Kathryn E.
    Meyers, Bryan F.
    Puri, Varun
    Kozower, Benjamin D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 164 (03): : 615 - +
  • [43] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Boklage, Susan
    Gouldin, Winston
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
  • [44] Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Felip Font, E.
    Gettinger, S. N.
    Burgio, M. A.
    Antonia, S. J.
    Holgado, E.
    Spigel, D. R.
    Arrieta, O.
    Domine Gomez, M.
    Aren Frontera, O.
    Brahmer, J.
    Chow, L. Q.
    Crino, L.
    Butts, C.
    Coudert, B.
    Horn, L.
    Steins, M.
    Geese, W. J.
    Li, A.
    Healey, D.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Three-Year Follow-Up From checkMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
    Felip, Enriqueta
    Gettinger, Scott
    Burgio, Marco Angelo
    Antonia, Scott J.
    Holgado, Esther
    Spigel, David
    Arrieta, Oscar
    Domine, Manuel
    Aren Frontera, Osvaldo
    Brahmer, Julie
    Chow, Laura Q.
    Crino, Lucio
    Butts, Charles
    Coudert, Bruno
    Horn, Leora
    Steins, Martin
    Geese, William J.
    Li, Ang
    Healey, Diane
    Vokes, Everett E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 142 - 143
  • [46] What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer
    Thomas W. LeBlanc
    Myles Nickolich
    Christel N. Rushing
    Gregory P. Samsa
    Susan C. Locke
    Amy P. Abernethy
    Supportive Care in Cancer, 2015, 23 : 3455 - 3463
  • [47] What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer
    LeBlanc, Thomas W.
    Nickolich, Myles
    Rushing, Christel N.
    Samsa, Gregory P.
    Locke, Susan C.
    Abernethy, Amy P.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (12) : 3455 - 3463
  • [48] EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES (PROS) WITH CRIZOTINIB VERSUS CHEMOTHERAPY IN ASIAN PATIENTS IN A PHASE III STUDY OF PREVIOUSLY TREATED ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Nishio, Makoto
    Hirsh, Vera
    Kim, Dong-Wan
    Wilner, Keith D.
    Polli, Anna
    Reisman, Arlene
    Iyer, Shrividya
    Blackhall, Fiona
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S198 - S199
  • [49] Docetaxel (Taxotere®) and Carboplatin in the treatment of advanced non-small lung cancer (NSCLC)
    Schutte, W
    Bork, I
    Wollschlager, B
    Schadlich, S
    ANNALS OF ONCOLOGY, 1998, 9 : 90 - 90
  • [50] Docetaxel in the management of advanced non-small cell lung cancer
    Miller, VA
    SEMINARS IN ONCOLOGY, 1998, 25 (03) : 15 - 19
12345